108TH CONGRESS

2D SESSION S. 2195

AN ACT

To amend the Controlled Substances Act to clarify the definition of anabolic steroids and to provide for research

and education activities relating to steroids and steroid

precursors.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the ‘‘Anabolic Steroid Con5 trol Act of 2004’’.
 †

2

S 2195 ES

1 SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES

2 ACT.

3 (a) DEFINITIONS.—Section 102 of the Controlled

4 Substances Act (21 U.S.C. 802) is amended—

5 (1) in paragraph (41)—

6 (A) by realigning the margin so as to align

7 with paragraph (40); and

8 (B) by striking subparagraph (A) and in9 serting the following:

10 ‘‘(A) The term ‘anabolic steroid’ means any drug or

11 hormonal substance, chemically and pharmacologically re12 lated to testosterone (other than estrogens, progestins,

13 corticosteroids, and dehydroepiandrosterone), and

14 includes—

15 ‘‘(i) androstanediol—

16 ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and

17 ‘‘(II) 3α,17β-dihydroxy-5α-androstane;

18 ‘‘(ii) androstanedione (5α-androstan-3,17-

19 dione);

20 ‘‘(iii) androstenediol—

21 ‘‘(I) 1-androstenediol (3β,17β-dihydroxy22 5α-androst-1-ene);

23 ‘‘(II) 1-androstenediol (3α,17β-dihydroxy24 5α-androst-1-ene);

25 ‘‘(III) 4-androstenediol (3β,17β-dihydroxy26 androst-4-ene); and
†

3

S 2195 ES

1 ‘‘(IV) 5-androstenediol (3β,17β-dihydroxy2 androst-5-ene);

3 ‘‘(iv) androstenedione—

4 ‘‘(I) 1-androstenedione ([5α]-androst-1-en5 3,17-dione);

6 ‘‘(II) 4-androstenedione (androst-4-en7 3,17-dione); and

8 ‘‘(III) 5-androstenedione (androst-5-en9 3,17-dione);

10 ‘‘(v) bolasterone (7α,17α-dimethyl-17β11 hydroxyandrost-4-en-3-one);

12 ‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene13 3-one);

14 ‘‘(vii) calusterone (7β,17α-dimethyl-17β15 hydroxyandrost-4-en-3-one);

16 ‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4-

17 en-3-one);

18 ‘‘(ix) dehydrochloromethyltestosterone (4-

19 chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3-

20 one);

21 ‘‘(x) >1-dihydrotestosterone (a.k.a. ‘1-testos22 terone’) (17β-hydroxy-5α-androst-1-en-3-one);

23 ‘‘(xi) 4-dihydrotestosterone (17β-hydroxy24 androstan-3-one);
†

4

S 2195 ES

1 ‘‘(xii) drostanolone (17β-hydroxy-2α-methyl-5α2 androstan-3-one);

3 ‘‘(xiii) ethylestrenol (17α-ethyl-17β-hydroxyestr4 4-ene);

5 ‘‘(xiv) fluoxymesterone (9-fluoro-17α-methyl6 11β,17β-dihydroxyandrost-4-en-3-one);

7 ‘‘(xv) formebolone (2-formyl-17α-methyl8 11α,17β-dihydroxyandrost-1,4-dien-3-one);

9 ‘‘(xvi) furazabol (17α-methyl-17β10 hydroxyandrostano[2,3-c]-furazan);

11 ‘‘(xvii) 13β-ethyl-17α-hydroxygon-4-en-3-one;

12 ‘‘(xviii) 4-hydroxytestosterone (4,17β-dihydroxy13 androst-4-en-3-one);

14 ‘‘(xix) 4-hydroxy-19-nortestosterone (4,17β15 dihydroxy-estr-4-en-3-one);

16 ‘‘(xx) mestanolone (17α-methyl-17β-hydroxy17 5α-androstan-3-one);

18 ‘‘(xxi) mesterolone (1α-methyl-17β-hydroxy19 [5α]-androstan-3-one);

20 ‘‘(xxii) methandienone (17α-methyl-17β21 hydroxyandrost-1,4-dien-3-one);

22 ‘‘(xxiii) methandriol (17α-methyl-3β,17β23 dihydroxyandrost-5-ene);

24 ‘‘(xxiv) methenolone (1-methyl-17β-hydroxy-5α25 androst-1-en-3-one);
†

5

S 2195 ES

1 ‘‘(xxv) 17α-methyl-3β, 17β-dihydroxy-5α-andro2 stane;

3 ‘‘(xxvi) 17α-methyl-3α,17β-dihydroxy-5α-andro4 stane;

5 ‘‘(xxvii) 17α-methyl-3β,17β-dihydroxyandrost-4-

6 ene.

7 ‘‘(xxviii) 17α-methyl-4-hydroxynandrolone

8 (17α-methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one);

9 ‘‘(xxix) methyldienolone (17α-methyl-17β10 hydroxyestra-4,9(10)-dien-3-one);

11 ‘‘(xxx) methyltrienolone (17α-methyl-17β12 hydroxyestra-4,9-11-trien-3-one);

13 ‘‘(xxxi) methyltestosterone (17α-methyl-17β14 hydroxyandrost-4-en-3-one);

15 ‘‘(xxxii) mibolerone (7α,17α-dimethyl-17β16 hydroxyestr-4-en-3-one);

17 ‘‘(xxxiii) 17α-methyl->1-dihydrotestosterone

18 (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one)

19 (a.k.a. ‘17-α-methyl-1-testosterone’);

20 ‘‘(xxxiv) nandrolone (17β-hydroxyestr-4-en-3-

21 one);

22 ‘‘(xxxv) norandrostenediol—

23 ‘‘(I) 19-nor-4-androstenediol (3β, 17β24 dihydroxyestr-4-ene);
†

6

S 2195 ES

1 ‘‘(II) 19-nor-4-androstenediol (3α, 17β2 dihydroxyestr-4-ene);

3 ‘‘(III) 19-nor-5-androstenediol (3β, 17β4 dihydroxyestr-5-ene); and

5 ‘‘(IV) 19-nor-5-androstenediol (3α, 17β6 dihydroxyestr-5-ene);

7 ‘‘(xxxvi) norandrostenedione—

8 ‘‘(I) 19-nor-4-androstenedione (estr-4-en9 3,17-dione); and

10 ‘‘(II) 19-nor-5-androstenedione (estr-5-en11 3,17-dione;

12 ‘‘(xxxvii) norbolethone (13β,17α-diethyl-17β13 hydroxygon-4-en-3-one);

14 ‘‘(xxxviii) norclostebol (4-chloro-17β15 hydroxyestr-4-en-3-one);

16 ‘‘(xxxix) norethandrolone (17α-ethyl-17β17 hydroxyestr-4-en-3-one);

18 ‘‘(xl) normethandrolone (17α-methyl-17β19 hydroxyestr-4-en-3-one);

20 ‘‘(xli) oxandrolone (17α-methyl-17β-hydroxy-2-

21 oxa-[5α]-androstan-3-one);

22 ‘‘(xlii) oxymesterone (17α-methyl-4,17β23 dihydroxyandrost-4-en-3-one);
†

7

S 2195 ES

1 ‘‘(xliii) oxymetholone (17α-methyl-2-

2 hydroxymethylene-17β-hydroxy-[5α]-androstan-3-

3 one);

4 ‘‘(xliv) stanozolol (17α-methyl-17α-hydroxy5 [5α]-androst-2-eno[3,2-c]-pyrazole);

6 ‘‘(xlv) stenbolone (17β-hydroxy-2-methyl-[5α]-

7 androst-1-en-3-one);

8 ‘‘(xlvi) testolactone (13-hydroxy-3-oxo-13,17-

9 secoandrosta-1,4-dien-17-oic acid lactone);

10 ‘‘(xlvii) testosterone (17β-hydroxyandrost-4-en11 3-one);

12 ‘‘(xlviii) tetrahydrogestrinone (13β,17α-diethyl13 17β-hydroxygon-4,9,11-trien-3-one);

14 ‘‘(xlix) trenbolone (17β-hydroxyestr-4,9,11-

15 trien-3-one); and

16 ‘‘(xlx) any salt, ester, or ether of a drug or sub17 stance described in this paragraph.

18 The substances excluded under this subparagraph may at

19 any time be scheduled by the Attorney General in accord20 ance with the authority and requirements of subsections

21 (a) through (c) of section 201.’’; and

22 (2) in paragraph (44), by inserting ‘‘anabolic

23 steroids,’’ after ‘‘marihuana,’’.
†

8

S 2195 ES

1 (b) AUTHORITY AND CRITERIA FOR CLASSIFICA2 TION.—Section 201(g) of the Controlled Substances Act

3 (21 U.S.C. 811(g)) is amended—

4 (1) in paragraph (1), by striking ‘‘substance

5 from a schedule if such substance’’ and inserting

6 ‘‘drug which contains a controlled substance from

7 the application of titles II and III of the Comprehen8 sive Drug Abuse Prevention and Control Act (21

9 U.S.C. 802 et seq.) if such drug’’; and

10 (2) in paragraph (3), by adding at the end the

11 following:

12 ‘‘(C) Upon the recommendation of the Sec13 retary of Health and Human Services, a compound,

14 mixture, or preparation which contains any anabolic

15 steroid, which is intended for administration to a

16 human being or an animal, and which, because of its

17 concentration, preparation, formulation or delivery

18 system, does not present any significant potential for

19 abuse.’’.

20 (c) ANABOLIC STEROIDS CONTROL ACT.—Section

21 1903 of the Anabolic Steroids Control Act of 1990 (Public

22 Law 101–647) is amended—

23 (1) by striking subsection (a); and

24 (2) by redesignating subsections (b) and (c) as

25 subsections (a) and (b), respectively.
†

9

S 2195 ES

1 (d) EFFECTIVE DATE.—The amendments made by

2 this section shall take effect 90 days after the date of en3 actment of this Act.

4 SEC. 3. SENTENCING COMMISSION GUIDELINES.

5 The United States Sentencing Commission shall—

6 (1) review the Federal sentencing guidelines

7 with respect to offenses involving anabolic steroids;

8 (2) consider amending the Federal sentencing

9 guidelines to provide for increased penalties with re10 spect to offenses involving anabolic steroids in a

11 manner that reflects the seriousness of such offenses

12 and the need to deter anabolic steroid trafficking

13 and use; and

14 (3) take such other action that the Commission

15 considers necessary to carry out this section.

16 SEC. 4. PREVENTION AND EDUCATION PROGRAMS.

17 (a) IN GENERAL.—The Secretary of Health and

18 Human Services (referred to in this Act as the ‘‘Sec19 retary’’) shall award grants to public and nonprofit private

20 entities to enable such entities to carry out science-based

21 education programs in elementary and secondary schools

22 to highlight the harmful effects of anabolic steroids.

23 (b) ELIGIBILITY.—

24 (1) APPLICATION.—To be eligible for grants

25 under subsection (a), an entity shall prepare and
†

10

S 2195 ES

1 submit to the Secretary an application at such time,

2 in such manner, and containing such information as

3 the Secretary may require.

4 (2) PREFERENCE.—In awarding grants under

5 subsection (a), the Secretary shall give preference to

6 applicants that intend to use grant funds to carry

7 out programs based on—

8 (A) the Athletes Training and Learning to

9 Avoid Steroids program;

10 (B) The Athletes Targeting Healthy Exer11 cise and Nutrition Alternatives program; and

12 (C) other programs determined to be effec13 tive by the National Institute on Drug Abuse.

14 (c) USE OF FUNDS.—Amounts received under a

15 grant under subsection (a) shall be used for education pro16 grams that will directly communicate with teachers, prin17 cipals, coaches, as well as elementary and secondary school

18 children concerning the harmful effects of anabolic

19 steroids.

20 (d) AUTHORIZATION OF APPROPRIATIONS.—There is

21 authorized to be appropriated to carry out this section,

22 $15,000,000 for each of fiscal years 2005 through 2010.

23 SEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH.

24 (a) IN GENERAL.—The Secretary of Health and

25 Human Services shall ensure that the National Survey on
†

11

S 2195 ES

1 Drug Use and Health includes questions concerning the

2 use of anabolic steroids.

3 (b) AUTHORIZATION OF APPROPRIATIONS.—There is

4 authorized to be appropriated to carry out this section,

5 $1,000,000 for each of fiscal years 2005 through 2010.

Passed the Senate October 6, 2004.

Attest:

Secretary.
108TH CONGRESS

2D SESSION S. 2195

AN ACT

To amend the Controlled Substances Act to clarify

steroids and steroid precursors.for research and education activities relating tothe definition of anabolic steroids and to provide